Description

Nisotirotide (LY-3457263) is a PYY analog agonist studied in type 2 diabetes and obesity[1].—–C230H343N59O65—-[1]Kloock S, et al. Obesity and its comorbidities, current treatment options and future perspectives: Challenging bariatric surgery? Pharmacol Ther. 2023 Nov;251:108549.–2663844-45-7–4974.53—-OC1=CC=C(C[C@H](NC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC([C@H]2N(CCC2)C([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC(CNC([C@H]3N(CCC3)C([C@@H](NC([C@@H](NC([C@H]4N(CCC4)C([C@@H](NC([C@H]5NCCC5)=O)CCCCN)=O)=O)CCC(O)=O)=O)CCCCNC(CCCCCNC([C@@H](NC(CC[C@H](NC(CCCCCCCCCCCCCCCCC(O)=O)=O)C(O)=O)=O)CCC(O)=O)=O)=O)=O)=O)=O)CCC(O)=O)=O)CC(O)=O)=O)C)=O)CO)=O)=O)CCC(O)=O)=O)CCC(O)=O)=O)CC6=CNC7=C6C=CC=C7)=O)CCC(N)=O)=O)CCCNC(N)=N)=O)CC8=CC=C(C=C8)O)=O)CC9=CC=C(C=C9)O)=O)C)=O)CCC(O)=O)=O)CC(C)C)=O)CCCNC(N)=N)=O)CC=CNC=N)=O)CC=CC=C(C=C)O)=O)CC(C)C)=O)CC(N)=O)=O)CC=CNC=CC=CC=C)=O)CC(C)C)=O)[C@@H](C)O)=O)CCCNC(N)=N)=O)CCC(N)=O)=O)CCCNC(N)=N)=O)C(N)=O)C=C1–Metabolic Disease–10 mM in DMSO–Others—-Others–Peptides